7.37
price up icon3.08%   0.22
after-market アフターアワーズ: 7.42 0.05 +0.68%
loading
前日終値:
$7.15
開ける:
$7.27
24時間の取引高:
675.63K
Relative Volume:
0.64
時価総額:
$365.15M
収益:
$89.04M
当期純損益:
$-241.08M
株価収益率:
-1.4011
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
-1.86%
1か月 パフォーマンス:
-12.99%
6か月 パフォーマンス:
-44.50%
1年 パフォーマンス:
-47.95%
1日の値動き範囲:
Value
$7.1825
$7.435
1週間の範囲:
Value
$6.56
$7.70
52週間の値動き範囲:
Value
$6.56
$28.80

Regenxbio Inc Stock (RGNX) Company Profile

Name
名前
Regenxbio Inc
Name
セクター
Healthcare (1174)
Name
電話
240-552-8181
Name
住所
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
職員
344
Name
Twitter
@REGENXBIO
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
RGNX's Discussions on Twitter

RGNX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RGNX
Regenxbio Inc
7.37 365.15M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.00 108.68B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
681.58 74.90B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
640.52 38.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
246.27 31.76B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
111.93 26.83B 3.30B -501.07M 1.03B -2.1146

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-15 再開されました Morgan Stanley Overweight
2024-10-10 再開されました Raymond James Outperform
2024-06-07 開始されました Goldman Buy
2024-03-11 開始されました H.C. Wainwright Buy
2024-03-08 アップグレード RBC Capital Mkts Sector Perform → Outperform
2024-03-06 アップグレード Leerink Partners Market Perform → Outperform
2024-02-21 再開されました Raymond James Outperform
2023-11-01 開始されました Stifel Buy
2023-06-02 開始されました Robert W. Baird Outperform
2022-06-23 開始されました Berenberg Buy
2021-12-15 開始されました Wedbush Neutral
2021-10-19 再開されました Morgan Stanley Overweight
2021-01-06 アップグレード Raymond James Outperform → Strong Buy
2020-12-16 開始されました UBS Buy
2020-06-25 再開されました BofA/Merrill Buy
2020-05-13 開始されました RBC Capital Mkts Sector Perform
2019-08-20 アップグレード SVB Leerink Underperform → Mkt Perform
2019-06-18 繰り返されました Chardan Capital Markets Buy
2019-06-14 再開されました Raymond James Outperform
2019-06-05 繰り返されました Chardan Capital Markets Buy
2019-02-25 アップグレード Evercore ISI In-line → Outperform
2019-02-05 アップグレード Raymond James Outperform → Strong Buy
2018-12-17 繰り返されました Chardan Capital Markets Buy
2018-11-08 繰り返されました BofA/Merrill Neutral
2018-08-08 繰り返されました Chardan Capital Markets Buy
2018-07-23 ダウングレード BofA/Merrill Buy → Neutral
2018-07-10 繰り返されました Chardan Capital Markets Buy
2018-05-09 繰り返されました Barclays Overweight
2018-04-09 繰り返されました Chardan Capital Markets Buy
2018-03-12 ダウングレード Evercore ISI Outperform → In-line
2018-02-13 開始されました Mizuho Neutral
2017-11-09 再開されました Morgan Stanley Overweight
すべてを表示

Regenxbio Inc (RGNX) 最新ニュース

pulisher
04:29 AM

Assenagon Asset Management S.A. Has $6.62 Million Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

04:29 AM
pulisher
Jan 18, 2025

Regenxbio and Nippon Shinyaku forge $810m gene therapy deal - MSN

Jan 18, 2025
pulisher
Jan 17, 2025

(RGNX) Technical Data - Stock Traders Daily

Jan 17, 2025
pulisher
Jan 17, 2025

Nippon Shinyaku, REGENXBIO partner for MPS treatments in U.S. and Asia -January 17, 2025 at 08:01 am EST - Marketscreener.com

Jan 17, 2025
pulisher
Jan 16, 2025

Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha

Jan 16, 2025
pulisher
Jan 16, 2025

Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku - Scrip

Jan 16, 2025
pulisher
Jan 16, 2025

REGENXBIO: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026 (NASDAQ:RGNX) - Seeking Alpha

Jan 16, 2025
pulisher
Jan 15, 2025

REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again (NASDAQ:RGNX) - Seeking Alpha

Jan 15, 2025
pulisher
Jan 15, 2025

Regenxbio, Nippon Shinyaku Partner for MPS II, MPS I Gene Therapies - Contract Pharma

Jan 15, 2025
pulisher
Jan 15, 2025

Regenxbio maintained at Buy rating by H.C. Wainwright post partnership announcement - Investing.com India

Jan 15, 2025
pulisher
Jan 15, 2025

Regenxbio maintained at Buy by H.C. Wainwright post partnership announcement - Investing.com Australia

Jan 15, 2025
pulisher
Jan 15, 2025

Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga

Jan 15, 2025
pulisher
Jan 15, 2025

REGENXBIO (NASDAQ:RGNX) Receives Buy Rating from HC Wainwright - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Regenxbio inks MPS drugs collab with Nippon Shinyaku - The Pharma Letter

Jan 15, 2025
pulisher
Jan 14, 2025

AbbVie, REGENXBIO advance gene therapy for eye diseases By Investing.com - Investing.com Australia

Jan 14, 2025
pulisher
Jan 14, 2025

Rockville’s RegenxBio Enters $810 Million Partnership with Japanese Firm to Launch New Treatments - The MoCoShow

Jan 14, 2025
pulisher
Jan 14, 2025

Rockville’s RegenxBio strikes potential $810M deal with Japan’s Nippon Shinyaku - The Business Journals

Jan 14, 2025
pulisher
Jan 14, 2025

Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku - BioPharma Dive

Jan 14, 2025
pulisher
Jan 14, 2025

Regenxbio stock hits 52-week low at $7.13 amid market challenges - Investing.com Australia

Jan 14, 2025
pulisher
Jan 14, 2025

RegenXBio Partners with Nippon Shinyaku on Gene Therapies - TipRanks

Jan 14, 2025
pulisher
Jan 14, 2025

Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku By Investing.com - Investing.com Australia

Jan 14, 2025
pulisher
Jan 14, 2025

Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases - Longview News-Journal

Jan 14, 2025
pulisher
Jan 14, 2025

Barclays PLC Raises Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

AbbVie, REGENXBIO advance gene therapy for eye diseases - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

AbbVie (ABBV) and REGENXBIO (RGNX) Announce Updates on the ABBV-RGX-314 Clinical Program - StreetInsider.com

Jan 13, 2025
pulisher
Jan 13, 2025

AbbVie and REGENXBIO Advance Revolutionary One-Time Gene Therapy for Vision Loss Treatment - StockTitan

Jan 13, 2025
pulisher
Jan 09, 2025

Regenxbio stock jumps 13% on positive data for DMD drug - MSN

Jan 09, 2025
pulisher
Jan 08, 2025

BlackRock, Inc. Reduces Stake in Regenxbio Inc: A Strategic Port - GuruFocus.com

Jan 08, 2025
pulisher
Jan 08, 2025

Jane Street Group LLC Sells 35,994 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Jan 08, 2025
pulisher
Jan 08, 2025

Regenxbio price target lowered to $22 from $25 at BofA - Yahoo Finance

Jan 08, 2025
pulisher
Jan 08, 2025

JPMorgan Chase & Co. Decreases Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Jan 08, 2025
pulisher
Jan 08, 2025

JPMorgan Chase & Co. Cuts Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Jan 08, 2025
pulisher
Jan 06, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Jan 06, 2025
pulisher
Jan 04, 2025

Principal Financial Group Inc. Sells 11,064 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Jan 04, 2025
pulisher
Jan 02, 2025

Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.

Jan 02, 2025
pulisher
Jan 01, 2025

Geode Capital Management LLC Raises Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Jan 01, 2025
pulisher
Jan 01, 2025

RGNX stock touches 52-week low at $7.15 amid market challenges - Investing.com Australia

Jan 01, 2025
pulisher
Dec 31, 2024

RGNX stock touches 52-week low at $7.15 amid market challenges By Investing.com - Investing.com South Africa

Dec 31, 2024
pulisher
Dec 30, 2024

Barclays PLC Purchases 67,948 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Dec 30, 2024
pulisher
Dec 30, 2024

Barclays PLC Has $1.22 Million Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Dec 30, 2024
pulisher
Dec 30, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Short Interest Up 18.4% in December - MarketBeat

Dec 30, 2024
pulisher
Dec 28, 2024

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive - Simply Wall St

Dec 28, 2024
pulisher
Dec 27, 2024

(RGNX) Investment Analysis - Stock Traders Daily

Dec 27, 2024
pulisher
Dec 26, 2024

Fmr LLC Boosts Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Dec 26, 2024

Regenxbio Inc (RGNX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Regenxbio Inc (RGNX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
KARABELAS ARGERIS N
Director
Oct 01 '24
Option Exercise
3.76
10,000
37,600
21,286
KARABELAS ARGERIS N
Director
Oct 01 '24
Sale
10.11
10,000
101,052
11,286
KARABELAS ARGERIS N
Director
Sep 03 '24
Option Exercise
3.76
10,000
37,600
21,286
KARABELAS ARGERIS N
Director
Sep 03 '24
Sale
11.56
10,000
115,588
11,286
Mills Kenneth T.
Director
Aug 08 '24
Option Exercise
0.85
36,316
30,869
444,351
KARABELAS ARGERIS N
Director
Aug 01 '24
Option Exercise
3.85
10,100
38,874
21,386
KARABELAS ARGERIS N
Director
Aug 01 '24
Sale
13.51
10,100
136,454
11,286
Simpson Curran
Chief Executive Officer
Aug 01 '24
Sale
15.00
100
1,500
170,037
$30.75
price down icon 0.65%
$71.93
price down icon 0.75%
$19.03
price up icon 4.62%
$358.93
price down icon 2.04%
biotechnology ONC
$210.08
price up icon 2.31%
$111.93
price down icon 0.74%
大文字化:     |  ボリューム (24 時間):